David McIntosh: From Western Dominance to LMIC Influence in Plasma Medicine with SK Plasma
David McIntosh, Founder and Chair of United Plasma Action, shared SK plasma’s post on LinkedIn:
“The wind is changing – and gathering force!!
After half a century of Western dominance in the field of vital plasma-derived medicines, Low and Middle Income Countries (LMIC) like Indonesia, India, Egypt, South Africa, and one or two other far-sighted pioneering nations are seizing the initiative.
Others will surely follow!
Most fellow LinkedIners are probably unaware of the fact that the only country in the World today that is collecting enough plasma for its own patients with some to spare for others overseas is the United States of America.
The US contribution to the current global total is over 70%.
No other country is making any significant contribution at all to the needs of its neighbours.
The US exports are life-savingly valuable.
Heaven knows what the World would do without them; but the situation can’t possible go on like this much longer.
Apart from anything else –
- even at 70% of the current total availability of plasma-derived medicines, worldwide, that’s less than 14% of what’s actually required, globally, to give all patients the treatments they need. (Shamefully, 80% of rare disease sufferers currently have to go without … )
- with a population of less than 400 million, the USA cannot possibly be expected to serve all the needs of a global population of over eight billion
- and – even if that were possible, it makes no sense for one of the highest cost countries in the World to be the sole supplier to over 100 poorer countries. It just makes no sense economically – and is likely to be unaffordable in any event
No – human plasma is one of the most ubiquitous and plentiful of all the raw materials needed to support Civilisation.
It’s as plentiful as raindrops and sunshine.
The LMIC parts of the World have as much of it as anyone else.
All that’s required is the determination that the pioneering LMIC nations are already showing – to Get out there and Collect It!!
More power to the LMIC elbow!
To SK plasma in particular at this auspicious time – Bravo!
And all best wishes for a huge success.”
SK Plasma shared a post on LinkedIn:
“We’re Hiring – Join SK Plasma Core Indonesia!
SKPlasma Core Indonesia is currently expanding our team and inviting talented, motivated, and passionate professionals to grow with us in the pharmaceutical manufacturing industry.
Open Positions:
- Drug Substance Team Manager and Supervisor
- Drug Substance Operator
- Drug Product Supervisor
- Drug Product Staff
- Production Support Team Manager
- Production Support Operator
- Utility Staff and Specialist
- Utility Engineer
- Biopharmaceutical QMS and GMP Compliance Supervisor
- QA (Qualification) Specialist
- Data Integrity Specialist
- QC Analyst
We look forward to welcoming passionate individuals who are ready to grow their careers and make meaningful impact in the healthcare sector.”
Find more posts featuring David McIntosh on Hemostasis Today.
-
May 22, 2026, 11:52Prakash W. Kamat: Highlighting the Role of Physical Activity in Hemophilia Management
-
May 22, 2026, 11:43Mohamed Hanafy Morsy: Understanding Hemochromatosis – Genetics Made Simple
-
May 22, 2026, 10:23Rucha Patil: Insights from The National Haemophilia Conclave 2026
-
May 22, 2026, 10:11Narat Srivali: New Systematic Review and Meta-Analysis on Glucocorticoid Therapy and The Risk of VTE
-
May 22, 2026, 10:02Greta Mulders: Nursing Leadership in Haemophilia Gene Therapy
-
May 22, 2026, 08:45Dirk Sibbing: Ethnicity and Antiplatelet Therapy Outcomes in CCS
-
May 22, 2026, 08:35Jason Brandon: On Lyophilized Hemostatic Supplementation at Simmons Research Day 2026
-
May 22, 2026, 08:28Inconsistent D-Dimer Assay Reporting in VTE Studies – JTH
-
May 22, 2026, 08:21Vincent Jongkind: We Invite You to Participate in a Delphi Study for a Core Outcome Set in Acute Limb Ischemia